Skip to main content
Spyre Therapeutics, Inc. logo

Spyre Therapeutics, Inc. — Investor Relations & Filings

Ticker · SYRE ISIN · US00773J1034 LEI · 52990017AIJPRH3HQH40 US Manufacturing
Open in API
Filings indexed 740 across all filing types
Latest filing 2021-04-22 Proxy Solicitation & In…
Country US United States of America
Listing US SYRE

About Spyre Therapeutics, Inc.

https://spyre.com/

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapeutics for patients with inflammatory bowel disease (IBD) and other immune-mediated conditions. The company's approach involves engineering novel antibodies with prolonged activity in the body, which allows for less frequent dosing. Its pipeline targets validated biological mechanisms and explores the use of these antibodies as both monotherapies and in rational combination therapies. Spyre aims to provide treatment options for various gastrointestinal and rheumatic diseases that offer the potential for enhanced efficacy and greater convenience.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2021-04-22 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement (a license and supply agreement) with another company, including financial terms and future obligations. There are no financial statements or detailed financial performance data presented, nor is this a transcript, presentation, or voting result. The document is not an annual or quarterly report but a regulatory announcement of a significant business event. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories.
2021-03-22 English
SCHEDULE 13D/A
Major Shareholding Notification
2021-03-19 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as equity incentive plans and employee stock purchase plans. It includes details about the number of shares to be registered, the plans under which they will be issued, and references to prior filings. It is not a financial report, earnings release, or management discussion, but rather a regulatory filing related to securities registration. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a report publication notice, but a full registration statement.
2021-03-18 English
10-K
Annual Report FY 2020
2021-03-18 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text indicates that the company issued a press release announcing financial results for the quarter ended December 31, 2020, and also updated its corporate presentation. The document itself does not contain the full financial results or detailed financial statements but references exhibits (press release and presentation) attached to the filing. The length is 4476 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of financial results and presentation updates, not the full earnings release or investor presentation themselves. Therefore, the best classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories like ER or IP.
2021-03-18 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.